PT - JOURNAL ARTICLE AU - Norton, Alice AU - De La Horra Gozalo, Arancha AU - de Colombi, Nicole Feune AU - Alobo, Moses AU - Asego, Juliette Mutheu AU - Al-Rawni, Zainab AU - Antonio, Emila AU - Parker, James AU - Mwangi, Wayne AU - Adhiambo, Colette AU - Marsh, Kevin AU - Bayona, Marta Tufet AU - Piot, Peter AU - Lang, Trudie TI - The remaining unknowns: A determination of the current research priorities for COVID-19 by the global health research community AID - 10.1101/2020.06.24.20138198 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.24.20138198 4099 - http://medrxiv.org/content/early/2020/06/24/2020.06.24.20138198.short 4100 - http://medrxiv.org/content/early/2020/06/24/2020.06.24.20138198.full AB - Background In March 2020 the World Health Organisation (WHO) released a Global Research Roadmap in an effort to coordinate and accelerate the global research response to combat COVID-19 based on deliberations of 400 experts across the world. Three months on, the disease and our understanding have both evolved significantly. As we now tackle a pandemic in very different contexts and with increased knowledge, we sought to build on the work of the WHO to gain a more current and global perspective on these initial priorities.Methods and findings We undertook a mixed methods study seeking the views of the global research community to i) assess which of the early WHO roadmap priorities are still most pressing; ii) understand whether they are still valid in different settings, regions or countries; and iii) identify any new emerging priorities.Thematic analysis of the significant body of combined data shows the WHO roadmap is globally relevant, however, new important priorities have emerged, in particular, pertinent to low and lower-middle income countries (less resourced countries), where health systems are under significant competing pressures. We also found a shift from prioritising vaccine and therapeutic development towards a focus on assessing the effectiveness, risks, benefits and trust in the variety of public health interventions and measures. Our findings also provide insight into temporal nature of these research priorities, highlighting the urgency of research that can only be undertaken within the period of virus transmission, as well as other important research questions but which can be answered outside the transmission period. Both types of studies are key to help combat this pandemic but also importantly to ensure we are better prepared for the future.Conclusions We hope these findings will help guide decision making across the broad research system including the multi-lateral partners, research funders, public health practitioners, clinicians and civil society.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe COVID-19 Knowledge hub is supported by a grant from UK Research and Innovation (https://www.ukri.org/ Grant number: MC_PC_19073). The Global Health Network is supported by a grant from the Bill and Melinda Gates Foundation (https://www.gatesfoundation.org/ Grant number: OPP1169808). No other specific funding supported this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was limited to seeking the views of healthcare professionals and research staff; patients and the wider community where not involved. Therefore, this research would be considered 'minimal risk' and does not come under the definition of research involving human subjects. However, this work does still fall with our research methodology and remit for the protocol that is approved by the University of Oxford Research Ethics Committee (OxTREC) protocol number OxTREC 541-18.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be fully available without restriction. URLs/accession numbers/DOIs will be available only after acceptance of the manuscript for publication so that we can ensure their inclusion before publication.